Pirfenidone use in fibrotic diseases: What do we know so far?

Torre A, Martínez-Sánchez FD, Narvaez-Chávez SM, Herrera-Islas MA, Aguilar-Salinas CA, Córdova-Gallardo J

Open source

DOI
10.1002/iid3.1335
Published
2024 Jul
Container
Immunity, inflammation and disease
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/iid3.1335,
  title = {Pirfenidone use in fibrotic diseases: What do we know so far?},
  author = {Torre A and Martínez-Sánchez FD and Narvaez-Chávez SM and Herrera-Islas MA and Aguilar-Salinas CA and Córdova-Gallardo J},
  year = {2024},
  journal = {Immunity, inflammation and disease},
  doi = {10.1002/iid3.1335},
  url = {https://doi.org/10.1002/iid3.1335}
}

RIS

TY  - JOUR
TI  - Pirfenidone use in fibrotic diseases: What do we know so far?
AU  - Torre A
AU  - Martínez-Sánchez FD
AU  - Narvaez-Chávez SM
AU  - Herrera-Islas MA
AU  - Aguilar-Salinas CA
AU  - Córdova-Gallardo J
PY  - 2024
JO  - Immunity, inflammation and disease
DO  - 10.1002/iid3.1335
UR  - https://doi.org/10.1002/iid3.1335
ER  - 

APA

A, T., FD, M., SM, N., MA, H., CA, A., & J, C. (2024). Pirfenidone use in fibrotic diseases: What do we know so far?. Immunity, inflammation and disease. https://doi.org/10.1002/iid3.1335

Source records